

Dr. Theresa M. Long, MD, MPH, FS




Areas of critical concern

- 1) First hand experience in emerging medical trends
- 2) Pfizer biodistribution study
- 3) DMED/ 5.3.6
- 4). Post-vaccination VAERS reports / alterations of medical records
- 5) Bioweapons the virus, the vaccine
- 6) Aviation Safety

Post-vaccination

- Onset of déjà vu symptoms
- Smelling this that are there, smell of something burning



2.6.5.5B. PHARMACOKINETICS: ORGAN DISTRIBUTION CONTINUED

Test Article: [3H]-Labelled LNP-mRNA formulation containing ALC-0315 and ALC-0159

Report Number: 185350

Species (Strain):	Rat (Wistar Han)													
Sex/Number of Animals:	Male and female/3 animals/sex/timepoint (21 animals/sex total for the 50 µg dose)													
Feeding Condition:	Fed adlibitum													
Method of Administration:	Intramuscular injection													
Please:	50 µg [3H]-08-A01-C0 (lot # NC-0552-1)													
Number of Doses:	1													
Detection:	Radioactivity quantitation using liquid scintillation counting													
Sampling Time (hour):	0.25, 1, 2, 4, 8, 24, and 48 hours post-injection													
Sample	Mean total lipid concentration (µg lipid equivalent/g (or mL) (males and females combined)							% of administered dose (males and females combined)						
	0.25 h	1 h	2 h	4 h	8 h	24 h	48 h	0.25 h	1 h	2 h	4 h	8 h	24 h	48 h
Adipose tissue	0.057	0.100	0.126	0.128	0.093	0.084	0.181	-	-	-	-	-	-	-
Adrenal glands	0.271	1.48	2.72	2.89	6.80	13.8	18.2	0.001	0.007	0.010	0.015	0.035	0.066	0.106
Bladder	0.041	0.130	0.146	0.167	0.148	0.247	0.365	0.000	0.001	0.001	0.001	0.001	0.002	0.002
Bone (femur)	0.091	0.195	0.266	0.276	0.340	0.342	0.687	-	-	-	-	-	-	-
Bone marrow (femur)	0.479	0.960	1.24	1.24	1.84	2.49	3.77	-	-	-	-	-	-	-
Brain	0.045	0.100	0.138	0.115	0.073	0.069	0.068	0.007	0.013	0.020	0.016	0.011	0.010	0.009
Eyes	0.010	0.035	0.052	0.067	0.059	0.091	0.112	0.000	0.001	0.001	0.002	0.002	0.002	0.003
Heart	0.282	1.03	1.40	0.987	0.790	0.451	0.546	0.018	0.056	0.084	0.060	0.042	0.027	0.030
Injection site	128	394	311	338	213	195	165	19.9	52.6	31.6	28.4	21.9	29.1	24.6
Kidneys	0.391	1.16	2.05	0.924	0.590	0.426	0.425	0.050	0.124	0.211	0.109	0.075	0.054	0.057
Large intestine	0.013	0.048	0.093	0.287	0.649	1.10	1.34	0.008	0.025	0.065	0.192	0.405	0.692	0.762
Liver	0.737	4.63	11.0	16.5	26.5	19.2	24.3	0.602	2.87	7.33	11.9	18.1	15.4	16.2
Lung	0.492	1.21	1.83	1.50	1.15	1.04	1.09	0.052	0.101	0.178	0.169	0.122	0.101	0.101

The Highest concentrations in Adrenals and Liver- may explain numerous abnormal liver function tests and intermittent spiking blood pressures

2.6.5.5B. PHARMACOKINETICS: ORGAN
DISTRIBUTION CONTINUED

Test Article: [3H]-Labelled LNP-mRNA formulation containing

ALC-0315 and ALC-0159 Report
Number: 185350


Sample	Total Lipid concentration (µg lipid equivalent/g [or mL]) (males and females combined)							% of Administered Dose (males and females combined)						
	0.25 h	1 h	2 h	4 h	8 h	24 h	48 h	0.25 h	1 h	2 h	4 h	8 h	24 h	48 h
Lymph (mandibular)	0.064	0.189	0.290	0.408	0.534	0.554	0.727	-	-	-	-	-	-	-
Lymph node (mesenteric)	0.050	0.146	0.530	0.489	0.689	0.985	1.37	-	-	-	-	-	-	-
Muscle	0.021	0.061	0.084	0.103	0.096	0.095	0.192	-	-	-	-	-	-	-
Ovaries (females)	0.104	1.34	1.64	2.34	3.09	5.24	12.3	0.001	0.009	0.008	0.016	0.025	0.037	0.095
Pancreas	0.081	0.207	0.414	0.380	0.294	0.358	0.599	0.003	0.007	0.014	0.015	0.015	0.011	0.019
Pituitary gland	0.339	0.645	0.868	0.854	0.405	0.478	0.694	0.000	0.001	0.001	0.001	0.000	0.000	0.001
Prostate (males)	0.061	0.091	0.128	0.157	0.150	0.183	0.170	0.001	0.001	0.002	0.003	0.003	0.004	0.003
Salivary glands	0.084	0.193	0.255	0.220	0.135	0.170	0.264	0.003	0.007	0.008	0.008	0.005	0.006	0.009
Skin	0.013	0.208	0.159	0.145	0.119	0.157	0.253	-	-	-	-	-	-	-
Small intestine	0.030	0.221	0.476	0.879	1.28	1.30	1.47	0.024	0.130	0.319	0.543	0.776	0.906	0.835
Spinal cord	0.043	0.097	0.169	0.250	0.106	0.085	0.112	0.001	0.002	0.002	0.003	0.001	0.001	0.001
Spleen	0.334	2.47	7.73	10.3	22.1	20.1	23.4	0.013	0.093	0.325	0.385	0.982	0.821	1.03
Stomach	0.017	0.065	0.115	0.144	0.268	0.152	0.215	0.006	0.019	0.034	0.030	0.040	0.037	0.039
Testis (Males)	0.031	0.042	0.079	0.129	0.146	0.304	0.320	0.007	0.010	0.017	0.030	0.034	0.074	0.074
Thymus	0.088	0.243	0.340	0.335	0.196	0.207	0.331	0.004	0.007	0.010	0.012	0.008	0.007	0.008
Thyroid	0.155	0.536	0.842	0.851	0.544	0.578	1.00	0.000	0.001	0.001	0.001	0.001	0.001	0.001
Uterus (females)	0.043	0.203	0.305	0.140	0.287	0.289	0.456	0.002	0.011	0.015	0.008	0.016	0.018	0.022
Whole blood	1.97	4.37	5.40	3.05	1.31	0.909	0.420	-	-	-	-	-	-	-
Plasma	3.97	8.13	8.90	6.50	2.36	1.78	0.805	-	-	-	-	-	-	-
Blood: plasma ratio	0.815	0.515	0.550	0.510	0.555	0.530	0.540	-	-	-	-	-	-	-

WE Were told the mRNA stayed in the muscle- clearly crosses the blood-brain barrier, with highest concentration in OVARIES = menstrual irregularities and infertility risk

ICD I26 Pulmonary Embolism

Counts	2016	2017	2018	2019	2020	2021
< 20	14	14	11	11	22	59
20-24	117	95	111	127	148	462
25-29	117	151	129	126	218	626
30-34	145	134	113	122	176	603
35-39	115	138	138	158	172	823
>= 40	170	169	166	172	232	916
Total	678	701	668	716	968	3,489


ICD I26 Pulmonary Embolisms across the DoD
2016-2021



G00 - G99 Diseases of the Nervous System

Counts	2016	2017	2018	2019	2020	2021
< 20	2,307	2,385	2,630	2,755	2,425	7,287
20-24	13,593	13,882	14,048	14,899	14,023	96,511
25-29	17,939	17,570	17,358	18,105	17,366	131,509
30-34	15,986	15,862	15,383	16,005	15,189	131,236
35-39	15,362	15,487	15,326	16,115	15,285	198,524
>= 40	17,248	16,812	16,637	17,133	16,498	297,946
Total	82,435	81,998	81,382	85,012	80,786	863,013

ICD G00 - G99 Diseases of the Nervous System
DoD 2016 to Nov 2021




C15 - C26 Malignant neoplasms of digestive organs

ICD C15 - C26 Malignant Neoplasms of Digestive Organs Across DoD (Active Duty) 2016-Oct2021

Counts	2016	2017	2018	2019	2020	Jan-Nov 2021
< 20	0	1	0	2	1	2
20-24	29	16	20	18	41	175
25-29	67	75	51	52	62	236
30-34	114	112	107	69	96	464
35-39	137	151	130	129	117	622
>= 40	313	299	325	332	387	2,561
Total	660	654	633	602	704	4,060

ICD C15 - C26 Malignant Neoplasms of Digestive Organs
DoD (Active Duty) 2016-Nov2021



Source: DMSS 1/19/2022

Rate calculated in counts per 1,000 persons per year. Data with unknown values excluded.


* Selected Diagnoses:

C15 - C26 Malignant neoplasms of digestive organs

C15 Malignant Neoplasm of Esophagus

Counts	2016	2017	2018	2019	2020	2021
< 20	0	0	0	0	0	0
20-24	3	1	0	0	2	3
25-29	3	5	7	8	4	0
30-34	1	5	6	0	2	30
35-39	10	5	3	4	5	69
>= 40	12	20	19	8	13	159
Total	29	36	35	20	26	261


ICD C15 Esophageal Cancer DoD 2016 to Nov 2021



E08 - E13 Diabetes Mellitus

Counts	2016	2017	2018	2019	2020	2021
< 20	58	56	84	87	82	141
20-24	567	533	501	490	500	2,039
25-29	617	638	516	525	560	2,154
30-34	646	596	509	543	589	2,144
35-39	873	731	728	783	690	4,182
>= 40	1,585	1,262	1,119	1,185	1,187	7,807
Total	4,346	3,816	3,457	3,613	3,608	18,467

ICD E08 - E13 Diabetes Mellitus DoD 2016-Nov 2021




Location: ALL LOCATIONS

E00 - E07 Disorders of Thyroid Gland

Counts	2016	2017	2018	2019	2020	2021
< 20	184	160	154	158	148	204
20-24	1,137	1,118	1,087	1,140	1,035	2,825
25-29	1,617	1,644	1,556	1,552	1,432	4,479
30-34	1,680	1,427	1,479	1,445	1,415	4,786
35-39	1,633	1,598	1,467	1,416	1,390	5,368
>= 40	1,827	1,747	1,614	1,578	1,473	7,107
Total	8,078	7,694	7,357	7,289	6,893	24,769


ICD E00 - E07 Disorders of Thyroid Gland DoD 2016 - Nov 2021




C73 - C75 Malignant neoplasms of thyroid and other endocrine glands

Counts	2016	2017	2018	2019	2020	2021
< 20	2	1	1	5	4	4
20-24	59	37	48	49	44	249
25-29	127	97	74	78	72	259
30-34	117	73	77	81	71	408
35-39	111	83	92	80	76	369
>= 40	134	103	77	81	105	661
Total	550	394	369	374	372	1,950

ICD C73 - C75
Cancer of Thyroid and Other Endocrine Glands
DoD 2016-Oct 2021



O




Population	2016	2017	2018	2019	2020
< 20	89,960.22	97,211.06	101,742.92	103,979.52	99,700.77
20-24	407,896.25	408,673.02	416,571.93	423,448.74	426,856.25
25-29	301,023.73	295,861.48	298,208.35	303,986.22	307,502.33
30-34	210,243.28	206,598.27	205,040.00	206,150.65	209,127.84
35-39	147,076.90	147,648.83	150,119.41	153,231.54	156,973.87
>= 40	132,655.89	127,672.92	124,588.75	124,232.43	126,871.55

Q00 - Q99 Congenital Malformations, Deformations and Chromosomal Abnormalities

Counts	2016	2017	2018	2019	2020	Jan-Oct 2021
< 20	439	499	498	541	430	702
20-24	2,690	2,646	2,485	2,625	2,401	4,821
25-29	2,915	2,527	2,428	2,541	2,305	4,217
30-34	2,166	2,124	1,862	2,040	1,790	3,202
35-39	1,749	1,605	1,635	1,667	1,610	3,028
>= 40	1,751	1,730	1,548	1,667	1,617	2,981
Total	11,710	11,131	10,456	11,081	10,153	18,951


ICD Q00 - Q99 Congenital Malformations, Deformations and Chromosomal Abnormalities
DoD 2016 to Oct 2021



K70 - K77 Diseases of liver


Counts	2016	2017	2018	2019	2020	2021
< 20	29	33	31	32	32	43
20-24	295	320	322	289	312	756
25-29	384	393	370	445	453	1,029
30-34	393	382	383	395	444	1,260
35-39	401	425	410	491	457	1,468
>= 40	492	500	547	582	624	2,274
Total	1,994	2,053	2,063	2,234	2,322	6,830

ICD K70 - K77 Diseases of Liver DoD Jan 2016 -Nov 2021



ICD C50 Malignant neoplasm of breast						
Counts	2016	2017	2018	2019	2020	Jan-Oct 2021
< 20	1	0	1	0	0	0
20-24	14	11	12	26	18	78
25-29	71	79	69	94	60	230
30-34	160	142	165	126	128	779
35-39	234	210	177	247	203	993
>= 40	454	368	342	299	357	2,277
Total	934	810	766	792	766	4,357

ICD C50 Malignant Neoplasm of Breast in DoD 2016-Oct 2021



Source: DMSS 1/19/2022


Rate calculated in counts per 1,000 persons per year. Data with unknown values excluded.

* Selected Diagnoses:

C50 Malignant neoplasm of breast

Total Number of Military Adverse Event Reports from VAERS By Year with superimposed DMED data

Data Source - VAERS Domestic data (by V_ADMINBY = MIL) - up to and including 2.11.2022/DMED -
Date Obtained 1.19.2022



BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

1p36 deletion syndrome; 2-Hydroxyglutaric aciduria; 5'nucleotidase increased; Acoustic neuritis; Acquired C1 inhibitor deficiency; Acquired epidermolysis bullosa; Acquired epileptic aphasia; Acute cutaneous lupus erythematosus; Acute disseminated encephalomyelitis; Acute encephalitis with refractory, repetitive partial seizures; Acute febrile neutrophilic dermatosis; Acute flaccid myelitis; Acute haemorrhagic leukoencephalitis; Acute haemorrhagic oedema of infancy; Acute kidney injury; Acute macular outer retinopathy; Acute motor axonal neuropathy; Acute motor-sensory axonal neuropathy; Acute myocardial infarction; Acute respiratory distress syndrome; Acute respiratory failure; Addison's disease; Administration site thrombosis; Administration site vasculitis; Adrenal thrombosis; Adverse event following immunisation; Ageusia; Agranulocytosis; Air embolism; Alanine aminotransferase abnormal; Alanine aminotransferase increased; Alcoholic seizure; Allergic bronchopulmonary mycosis; Allergic oedema; Alloimmune hepatitis; Alopecia areata; Alpers disease; Alveolar proteinosis; Ammonia abnormal; Ammonia increased; Amniotic cavity infection; Amygdalohippocampectomy; Amyloid arthropathy; Amyloidosis; Amyloidosis senile; Anaphylactic reaction; Anaphylactic shock; Anaphylactic transfusion reaction; Anaphylactoid reaction; Anaphylactoid shock; Anaphylactoid syndrome of pregnancy; Angioedema; Angiopathic neuropathy; Ankylosing spondylitis; Anosmia; Antiacetylcholine receptor antibody positive; Anti-actin antibody positive; Anti-aquaporin-4 antibody positive; Anti-basal ganglia antibody positive; Anti-cyclic citrullinated peptide antibody positive; Anti-epithelial antibody positive; Anti-erythrocyte antibody positive; Anti-exosome complex antibody positive; Anti-GAD antibody negative; Anti-GAD antibody positive; Anti-ganglioside antibody positive; Anti-gliadin antibody positive; Anti-glomerular basement membrane antibody positive; Anti-glomerular basement membrane disease; Anti-glycyl-tRNA synthetase antibody positive; Anti-HLA antibody test positive; Anti-IA2 antibody positive; Anti-insulin antibody increased; Anti-insulin antibody positive; Anti-insulin receptor antibody increased; Anti-insulin receptor antibody positive; Anti-interferon antibody negative; Anti-interferon antibody positive; Anti-islet cell antibody positive; Antimitochondrial antibody positive; Anti-muscle specific kinase antibody positive; Anti-myelin-associated glycoprotein antibodies positive; Anti-myelin-associated glycoprotein associated polyneuropathy; Antimyocardial antibody positive; Anti-neuronal antibody positive; Antineutrophil cytoplasmic antibody increased; Antineutrophil cytoplasmic antibody positive; Anti-neutrophil cytoplasmic antibody positive vasculitis; Anti-NMDA antibody positive; Antinuclear antibody increased; Antinuclear antibody positive; Antiphospholipid antibodies positive; Antiphospholipid syndrome; Anti-platelet antibody positive; Anti-prothrombin antibody positive; Antiribosomal P antibody positive; Anti-RNA polymerase III antibody positive; Anti-saccharomyces cerevisiae antibody test positive; Anti-sperm antibody positive; Anti-SRP antibody positive; Antisynthetase syndrome; Anti-thyroid antibody positive; Anti-transglutaminase antibody increased; Anti-VGCC antibody positive; Anti-VGKC antibody positive; Anti-vimentin antibody positive; Antiviral prophylaxis; Antiviral treatment; Anti-zinc transporter 8 antibody positive; Aortic embolus; Aortic thrombosis; Aortitis; Aplasia pure red cell; Aplastic anaemia; Application site thrombosis; Application site vasculitis; Arrhythmia; Arterial bypass occlusion; Arterial bypass thrombosis; Arterial thrombosis; Arteriovenous fistula thrombosis; Arteriovenous graft site stenosis; Arteriovenous graft thrombosis; Arteritis; Arteritis

CONFIDENTIAL

Page 2

BLUE: SERIOUS RISK TO SAFETY OF FLIGHT
YELLOW: SEEN in IAB Soldiers
ORANGE: SEEN in LYSTER STAFF
PINK: PEDIATRIC

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

coronary; Arthralgia; Arthritis; Arthritis enteropathic; Ascites; Aseptic cavernous sinus thrombosis; Aspartate aminotransferase abnormal; Aspartate aminotransferase increased; Aspartate-glutamate-transporter deficiency; AST to platelet ratio index increased; AST/ALT ratio abnormal; Asthma; Asymptomatic COVID-19; Ataxia; Atheroembolism; Atonic seizures; Atrial thrombosis; Atrophic thyroiditis; Atypical benign partial epilepsy; Atypical pneumonia; Aura; Autoantibody positive; Autoimmune anaemia; Autoimmune aplastic anaemia; Autoimmune arthritis; Autoimmune blistering disease; Autoimmune cholangitis; Autoimmune colitis; Autoimmune demyelinating disease; Autoimmune dermatitis; Autoimmune disorder; Autoimmune encephalopathy; Autoimmune endocrine disorder; Autoimmune enteropathy; Autoimmune eye disorder; Autoimmune haemolytic anaemia; Autoimmune heparin-induced thrombocytopenia; Autoimmune hepatitis; Autoimmune hyperlipidaemia; Autoimmune hypothyroidism; Autoimmune inner ear disease; Autoimmune lung disease; Autoimmune lymphoproliferative syndrome; Autoimmune myocarditis; Autoimmune myositis; Autoimmune nephritis; Autoimmune neuropathy; Autoimmune neutropenia; Autoimmune pancreatitis; Autoimmune pancytopenia; Autoimmune pericarditis; Autoimmune retinopathy; Autoimmune thyroid disorder; Autoimmune thyroiditis; Autoimmune uveitis; Autoinflammation with infantile enterocolitis; Autoinflammatory disease; Automatism epileptic; Autonomic nervous system imbalance; Autonomic seizure; Axial spondyloarthritis; Axillary vein thrombosis; Axonal and demyelinating polyneuropathy; Axonal neuropathy; Bacterascites; Baltic myoclonic epilepsy; Band sensation; Basedow's disease; Basilar artery thrombosis; Basophilopenia; B-cell aplasia; Behcet's syndrome; Benign ethnic neutropenia; Benign familial neonatal convulsions; Benign familial pemphigus; Benign rolandic epilepsy; Beta-2 glycoprotein antibody positive; Bickerstaff's encephalitis; Bile output abnormal; Bile output decreased; Biliary ascites; Bilirubin conjugated abnormal; Bilirubin conjugated increased; Bilirubin urine present; Biopsy liver abnormal; Biotinidase deficiency; Birdshot chorioretinopathy; Blood alkaline phosphatase abnormal; Blood alkaline phosphatase increased; Blood bilirubin abnormal; Blood bilirubin increased; Blood bilirubin unconjugated increased; Blood cholinesterase abnormal; Blood cholinesterase decreased; Blood pressure decreased; Blood pressure diastolic decreased; Blood pressure systolic decreased; Blue toe syndrome; Brachiocephalic vein thrombosis; Brain stem embolism; Brain stem thrombosis; Bromosulphthalein test abnormal; Bronchial oedema; Bronchitis; Bronchitis mycoplasma; Bronchitis viral; Bronchopulmonary aspergillosis allergic; Bronchospasm; Budd-Chiari syndrome; Bulbar palsy; Butterfly rash; C1q nephropathy; Caesarean section; Calcium embolism; Capillaritis; Caplan's syndrome; Cardiac amyloidosis; Cardiac arrest; Cardiac failure; Cardiac failure acute; Cardiac sarcoidosis; Cardiac ventricular thrombosis; Cardiogenic shock; Cardiolipin antibody positive; Cardiopulmonary failure; Cardio-respiratory arrest; Cardio-respiratory distress; Cardiovascular insufficiency; Carotid arterial embolus; Carotid artery thrombosis; Cataplexy; Catheter site thrombosis; Catheter site vasculitis; Cavernous sinus thrombosis; CDKL5 deficiency disorder; CEC syndrome; Cement embolism; Central nervous system lupus; Central nervous system vasculitis; Cerebellar artery thrombosis; Cerebellar embolism; Cerebral amyloid angiopathy; Cerebral arteritis; Cerebral artery embolism; Cerebral artery thrombosis; Cerebral gas embolism; Cerebral microembolism; Cerebral septic infarct; Cerebral thrombosis; Cerebral venous sinus thrombosis; Cerebral venous thrombosis; Cerebrospinal thrombotic

CONFIDENTIAL

Page 2

FDA-CBER-2021-5683-0000084

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

increased; Liver opacity; Liver palpable; Liver sarcoidosis; Liver scan abnormal; Liver tenderness; Low birth weight baby; Lower respiratory tract herpes infection; Lower respiratory tract infection; Lower respiratory tract infection viral; Lung abscess; Lupoid hepatic cirrhosis; Lupus cystitis; Lupus encephalitis; Lupus endocarditis; Lupus enteritis; Lupus hepatitis; Lupus myocarditis; Lupus myositis; Lupus nephritis; Lupus pancreatitis; Lupus pleurisy; Lupus pneumonitis; Lupus vasculitis; Lupus-like syndrome; Lymphocytic hypophysitis; Lymphocytopenia neonatal; Lymphopenia; MAGIC syndrome; Magnetic resonance imaging liver abnormal; Magnetic resonance proton density fat fraction measurement; Mahler sign; Manufacturing laboratory analytical testing issue; Manufacturing materials issue; Manufacturing production issue; Marburg's variant multiple sclerosis; Marchiafava-Bignami disease; Marine Lenhart syndrome; Mastocytic enterocolitis; Maternal exposure during pregnancy; Medical device site thrombosis; Medical device site vasculitis; MELAS syndrome; Meningitis; Meningitis aseptic; Meningitis herpes; Meningoencephalitis herpes simplex neonatal; Meningoencephalitis herpetic; Meningomyelitis herpes; MERS-CoV test; MERS-CoV test negative; MERS-CoV test positive; Mesangioproliferative glomerulonephritis; Mesenteric artery embolism; Mesenteric artery thrombosis; Mesenteric vein thrombosis; Metapneumovirus infection; Metastatic cutaneous Crohn's disease; Metastatic pulmonary embolism; Microangiopathy; Microembolism; Microscopic polyangiitis; Middle East respiratory syndrome; Migraine-triggered seizure; Miliary pneumonia; Miller Fisher syndrome; Mitochondrial aspartate aminotransferase increased; Mixed connective tissue disease; Model for end stage liver disease score abnormal; Model for end stage liver disease score increased; Molar ratio of total branched-chain amino acid to tyrosine; Molybdenum cofactor deficiency; Monocytopenia; Mononeuritis; Mononeuropathy multiplex; Morphoea; Morvan syndrome; Mouth swelling; Moyamoya disease; Multifocal motor neuropathy; Multiple organ dysfunction syndrome; Multiple sclerosis; Multiple sclerosis relapse; Multiple sclerosis relapse prophylaxis; Multiple subpial transection; Multisystem inflammatory syndrome in children; Muscular sarcoidosis; Myasthenia gravis; Myasthenia gravis crisis; Myasthenia gravis neonatal; Myasthenic syndrome; Myelitis; Myelitis transverse; Myocardial infarction; Myocarditis; Myocarditis post infection; Myoclonic epilepsy; Myoclonic epilepsy and ragged-red fibres; Myokymia; Myositis; Narcolepsy; Nasal herpes; Nasal obstruction; Necrotising herpetic retinopathy; Neonatal Crohn's disease; Neonatal epileptic seizure; Neonatal lupus erythematosus; Neonatal mucocutaneous herpes simplex; Neonatal pneumonia; Neonatal seizure; Nephritis; Nephrogenic systemic fibrosis; Neuralgic amyotrophy; Neuritis; Neuritis cranial; Neuromyelitis optica pseudo relapse; Neuromyelitis optica spectrum disorder; Neuromyotonia; Neuronal neuropathy; Neuropathy peripheral; Neuropathy, ataxia, retinitis pigmentosa syndrome; Neuropsychiatric lupus; Neurosarcoidosis; Neutropenia; Neutropenia neonatal; Neutropenic colitis; Neutropenic infection; Neutropenic sepsis; Nodular vasculitis; Noninfectious myelitis; Noninfective encephalitis; Noninfective encephalomyelitis; Noninfective oophoritis; Obstetrical pulmonary embolism; Occupational exposure to communicable disease; Occupational exposure to SARS-CoV-2; Ocular hyperaemia; Ocular myasthenia; Ocular pemphigoid; Ocular sarcoidosis; Ocular vasculitis; Oculofacial paralysis; Oedema; Oedema blister; Oedema due to hepatic disease; Oedema mouth; Oesophageal achalasia; Ophthalmic artery thrombosis; Ophthalmic herpes simplex; Ophthalmic herpes zoster; Ophthalmic vein thrombosis; Optic neuritis; Optic

CONFIDENTIAL

Page 6

FDA-CBER-2021-5683-0000088

Page 35

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

neonatal; Thrombophlebitis septic; Thrombophlebitis superficial; Thromboplastin antibody positive; Thrombosis; Thrombosis corpora cavernosa; Thrombosis in device; Thrombosis mesenteric vessel; Thrombotic cerebral infarction; Thrombotic microangiopathy; Thrombotic stroke; Thrombotic thrombocytopenic purpura; Thyroid disorder; Thyroid stimulating immunoglobulin increased; Thyroiditis; Tongue amyloidosis; Tongue biting; Tongue oedema; Tonic clonic movements; Tonic convulsion; Tonic posturing; Topectomy; Total bile acids increased; Toxic epidermal necrolysis; Toxic leukoencephalopathy; Toxic oil syndrome; Tracheal obstruction; Tracheal oedema; Tracheobronchitis; Tracheobronchitis mycoplasmal; Tracheobronchitis viral; Transaminases abnormal; Transaminases increased; Transfusion-related alloimmune neutropenia; Transient epileptic amnesia; Transverse sinus thrombosis; Trigeminal nerve paresis; Trigeminal neuralgia; Trigeminal palsy; Truncus coeliacus thrombosis; Tuberosus sclerosis complex; Tubulointerstitial nephritis and uveitis syndrome; Tumefactive multiple sclerosis; Tumour embolism; Tumour thrombosis; Type 1 diabetes mellitus; Type I hypersensitivity; Type III immune complex mediated reaction; Uhthoff's phenomenon; Ulcerative keratitis; Ultrasound liver abnormal; Umbilical cord thrombosis; Uncinate fits; Undifferentiated connective tissue disease; Upper airway obstruction; Urine bilirubin increased; Urobilinogen urine decreased; Urobilinogen urine increased; Urticaria; Urticaria papular; Urticarial vasculitis; Uterine rupture; Uveitis; Vaccination site thrombosis; Vaccination site vasculitis; Vagus nerve paralysis; Varicella; Varicella keratitis; Varicella post vaccine; Varicella zoster gastritis; Varicella zoster oesophagitis; Varicella zoster pneumonia; Varicella zoster sepsis; Varicella zoster virus infection; Vasa praevia; Vascular graft thrombosis; Vascular pseudoaneurysm thrombosis; Vascular purpura; Vascular stent thrombosis; Vasculitic rash; Vasculitic ulcer; Vasculitis; Vasculitis gastrointestinal; Vasculitis necrotising; Vena cava embolism; Vena cava thrombosis; Venous intravasation; Venous recanalisation; Venous thrombosis; Venous thrombosis in pregnancy; Venous thrombosis limb; Venous thrombosis neonatal; Vertebral artery thrombosis; Vessel puncture site thrombosis; Visceral venous thrombosis; Vllth nerve paralysis; Vllth nerve paresis; Vitiligo; Vocal cord paralysis; Vocal cord paresis; Vogt-Koyanagi-Harada disease; Warm type haemolytic anaemia; Wheezing; White nipple sign; Xllth nerve paralysis; X-ray hepatobiliary abnormal; Young's syndrome; Zika virus associated Guillain Barre syndrome.

CONFIDENTIAL

Page 9

FDA-CBER-2021-5683-0000091

Page 38

FDA Safety Surveillance of COVID-19 Vaccines :

DRAFT Working list of possible adverse event outcomes

Subject to change

This side effects appeared for a split second at 2:33:40 in an FDA presentation on October 22, 2020

- Guillain-Barré syndrome
- Acute disseminated encephalomyelitis
- Transverse myelitis
- Encephalitis/myelitis/encephalomyelitis/meningoencephalitis/meningitis/encepholopathy
- Convulsions/seizures
- Stroke
- Narcolepsy and cataplexy
- Anaphylaxis
- Acute myocardial infarction
- Myocarditis/pericarditis
- Autoimmune disease
- Deaths
- Pregnancy and birth outcomes
- Other acute demyelinating diseases
- Non-anaphylactic allergic reactions
- Thrombocytopenia
- Disseminated intravascular coagulation
- Venous thromboembolism
- Arthritis and arthralgia/joint pain
- Kawasaki disease
- Multisystem Inflammatory Syndrome in Children
- Vaccine enhanced disease

Linked PDF - Hover over studies for links to documents.



Is the SARS-CoV-2 Virus Spike Protein Architecture a Bio-Weapon?

Yes, per Anthony Fauci's March 11, 2020 email, "Coronavirus bioweapon production method." See pg 2286 of June 2 FOIA




Spike Proteins Contain Neurotoxic Sequences Found in Rabies Virus, Cobra Toxins, and a Prion-like domain

Viruses have sequences in their structure - similar to a computer program or a "recipe".
The Furin Cleavage site (PRRA) structure is ~~not found in any other SARS-CoV virus~~ found in virus patents since 2008 with characteristics found in Rabies virus that enables penetration of the blood brain barrier and Cobra venom which can create clotting or low platelet blood issues and neurological toxicity.


Study #1 05/21/20, "An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations"

SARS-CoV-2 (671-692)	C A S Y Q T T N S P R R A R S V A S Q S I
Bat SARS-like CoV RaTG13	C A S Y Q T T N S . . . R S V A S Q S I
Bat SARS-like CoV WIV16	C A S Y H T V S S L . . . R T S Q K S I
Bat SARS-like CoV WIV1	C A S Y H T V S S L . . . R T S Q K S I
SARS-CoV A031	C A S Y H T V S S L . . . R T S Q K S I
SARS-CoV A022	C A S Y H T V S S L . . . R T S Q K S I
SARS-CoV Urbani	C A S Y H T V S S L . . . R T S Q K S I
SARS-CoV CUHK-W1	C A S Y H T V S S L . . . R T S Q K S I
SARS-CoV GZ02	C A S Y H T V S L . . . R S T S Q K S I



Each "red triangle" depicts a Virus Spike Protein that contains sequences of HIV, PRRA, and the "Prion-like" structure.

Study #3 03/24/21, "SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration"



Study #2 05/21/20- "A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells"

The insertion of PRRA together with adjacent amino acid building blocks forms peptide sequence (a structure) common to that of neurotoxins found in Rabies, Cobra toxins, Bungarus snake venom and HIV.
See table study above.

Study #4* 01/15/21, "Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice."
SARS-CoV-2 virus kills mice from spongiform encephalopathy n 14 days = 1.5 human yrs.

* Boston University School of Medicine

Study #5 02/23/21, "SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques (monkeys)."